Martin Shkreli Auctions Chance to Punch Him in Face

Chris Gaetano
Published Date:
Sep 28, 2016
By Pavel Ševela, CC BY-SA 4.0

Ever look at Martin Shkreli, the man who dramatically raised the price of a life-saving AIDS drug, and wanted to punch him in the face? Well, for the right price, now you can: the infamous financier is auctioning off a chance to take your best shot at him for charity, according to Time, specifically to help the son of a friend who recently died of cancer. 

Shkreli, whom multiple news outlets have dubbed the most hated man in America, became infamous by purchasing the patent for a drug, Daraprim, used to treat a parasitic infection that is deadly to patients with weakened immune systems, and then raising its price from $13.50 a pill to $750. While public outrage initially led him to consider lowering the cost, he then reversed that decision and said, instead, that he should have made it even more expensive. He also bought the only copy of a new album by the Wu Tang Clan for $2 million, but said he probably won't listen to it.

He was also arrested for securities fraud in December--the government believes he took stock from Retrophin Inc., a pharmaceutical firm he started and was later fired from, in order to pay off debts from other business dealings, such as those associated with MSMB Capital, a hedge fund he previously managed that went on to lose millions. He has also been accused of lying about retaining an independent auditor during his tenure at MSMB Capital. The complaint against him claims that Shkreli claimed his company had $35 million in assets under management and that this had been confirmed by an independent auditor when, in truth, there was no independent auditor and the fund only had $700. 

Needless to say, many have taken him up on the offer to punch him in the face since he first announced it two day ago. 

UPDATE: As of 11 minutes ago, the bidding has closed and a woman from Florida has won the right to pummel Shkreli repeatedly in the face for $50,000. 

Click here to see more of the latest news from the NYSSCPA.